Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis - PubMed
a day ago
- #weight-loss
- #incretin-therapy
- #obesity
- Incretin-based dual and triple agonists show significant weight loss in obese individuals.
- These therapies also improve metabolic outcomes like waist circumference, glycated hemoglobin, and fasting plasma glucose.
- Higher risks of adverse events, including gastrointestinal issues and hypoglycemic episodes, were noted.
- No significant difference was found in serious adverse events compared to placebo.
- The study analyzed 10 randomized controlled trials involving 3236 participants.